Patient-reported outcomes from the MIRASOL trial: mirvetuximab soratansine versus chemotherapy for FRα-positive, platinum-resistant ovarian cancer

Mirvetuximab soravtansine-gynx (MRIV) is an antibody-drug conjugate targeting folate receptor α (FRα). The multinational phase 3 MIRASOL trial found that MIRV, compared with investigator’s choice of chemotherapy, improved progression-free survival and overall survival of patients with FRα-positive platinum-resistant ovarian cancer (PROC). Patient reported outcomes from MIRASOL have now been published. Improvement of abdominal and gastrointestinal scores after 8 or 9 weeks of treatment were reported by 21.0% of patients in the MIRV group and 15.3% of patients in the chemotherapy group (OR 1.5; p=0.26). The authors conclude that MIRV did not impair or improve patient quality of life compared with investigator’s choice of chemotherapy. The similar quality-of-life outcomes in the two groups, combined with the previously reported higher efficacy of MIRV compared with chemotherapy, support MIRV as new treatment option for FRα-positive PROC.